Drug intelligence / Profile preview

Optiject

Development stage: Unknown
Lead developer: Guerbet
Modality: Small Molecules
Administration: Intravenous, Intra-arterial

Overview

**Optiject** is a pre-filled syringe formulation of ioversol, a non-ionic iodinated contrast agent used for diagnostic imaging. It enables precise delivery via manual or automatic injection for procedures such as angiography, CT scans, and excretory urography, enhancing visualization of blood vessels, organs, and tissues. Developed for intravascular administration, it minimizes risks associated with traditional vials by providing ready-to-use syringes, first introduced in pre-filled form in 1996.

Brand names: Optiject
Other names: Optiray

Beyond the preview

Go deeper on Optiject.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optiject.

Explore the full profile